Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Xuanzhu Out-Licenses China Rights for Two Antibiotics in $66 Million Deal

publication date: Jun 22, 2022

Xuanzhu Biopharm of Shandong out-licensed China rights for two anti-infectives to Shanghai SPH New Asia Pharma in a $66 million agreement. New Asia will have rights to manufacture and sell Benapenem and Plazomicin in Greater China. Benapenem is a class 1.1 carbapenem antibiotic developed by Xuanzhu. Plazomicin is a next-gen semi-synthetic aminoglycoside antibiotic acquired by Xuanzhu from Achaogen, a US company. Xuanzhu is a non-wholly owned subsidiary of Sihuan Pharma, and New Asia, one of China’s largest antibiotic makers, is a non-wholly owned subsidiary of Shanghai Pharma. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
September 13-16, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022